Infusion therapy represents one of the greatest advancements in modern medicine, offering patients life-changing treatments for chronic and complex conditions like autoimmune diseases, cancer, and neurological disorders.
These therapies provide relief, improve quality of life, and, in many cases, offer the only viable treatment option for those suffering from debilitating illnesses. There are more than 60 independent infusion centers across the State of Oklahoma that ensure these treatments are accessible, costeffective, and high quality. However, their ability to serve patients is being undermined by a federal drug discount program that has veered far from its intended purpose, prioritizing hospital profits over patient care.
The 340B Drug Pricing Program was originally designed to help vulnerable patients access medications and care at reduced costs. Instead, it has become a profit-generating mechanism for large hospitals and health systems—at the expense of independent providers and, ultimately, patients. With the introduction of House Bill 2048, Oklahoma risks further entrenching this broken system rather than reforming it.
